An observational study in Cerebral Vein Thrombosis and Cerebral Venous Sinus Thrombosis, sponsored by Capital Medical University. Completed at 1 site in China. Per ClinicalTrials.gov, last updated 2024-02-26.
Sponsored by Capital Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Intracranial Thrombosis with a site in China — 6 open to participants now, 6 under way, 1 of them phase 3. Intracranial Thrombosis · China.
Among the 11 studies in Intracranial Thrombosis with a site in China, this one is one of 2 that started in 2022, is one of 6 observational ones, and was the 3rd registered.
46 studies on the registry are indexed under Intracranial Thrombosis; 15 are open to participants now.
Browse Intracranial Thrombosis studies →6 of the 11 studies in Intracranial Thrombosis with a site in China are open now. Recruiting first, the newest first:
Tianjin Medical University · Sites in China
Ages 18–90 · Healthy volunteers
Xuanwu Hospital, Beijing · Sites in China
Ages 18–80
Xuanwu Hospital, Beijing · Sites in China
Ages 18+
Xuanwu Hospital, Beijing · Sites in China
Ages 18–80
Capital Medical University · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 14 Intracranial Thrombosis studies recruiting now, 7 (50%) set no upper age limit and 2 (14%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 3 · Phase 4 1
First in 2011; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,276 is above the median of 319 across 26 observational studies indexed under Intracranial Thrombosis.
Median enrollment 80 across the 5 interventional studies, 387 across the 6 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 6 most frequent:
Capital Medical University is the lead sponsor of 296 studies on the registry; 90 are open to participants now.
Capital Medical University has 3 studies filed under Intracranial Thrombosis — fewer than ten, so there is no comparison to draw.
1 of the studies in Intracranial Thrombosis with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06658197Phase 3Xuanwu Hospital, BeijingEfficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Intracranial Thrombosis with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will investigate the epidemiology, risk factors, diagnostics, treatment, and the long-term prognosis of cerebral venous thrombosis in China.
The epidemiology, risk factors, diagnosis and treatment of Cerebral Venous Thrombosis (CVT) in China are still unclear. A retrospective hospital-based study will be conducted at fifty different hospitals across 31 provinces in China. This study will use ICD-10 to search patients diagnosed with CVT between January 1, 2018 and June 15, 2022 across 31 provinces and municipalities of 104 hospitals in China. Risk factors, clinical and radiological findings, treatment and short-term outcomes will be recorded from the hospital record system. Finally, a prospective follow-up will be conducted for all of the patients enrolled above. By combining data collected from retrospective hospital records with the new follow-up, it will be possible to better understand the epidemiology, risk factors, diagnosis, treatment and the long-term prognosis of CVT in China.
Patients with cerebral venous sinus thrombosis, deep cerebral vein thrombosis and cortical vein thrombosis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Favorable clinical outcome (modified Rankin score 0-1)
Time frame: Baseline to three years
All-cause mortality
A combination of death form of all causes
Time frame: Baseline to three years
Recurrence of cerebral venous thrombosis
Diagnosed by DSA, MRV, CTV or HR-MRI
Time frame: Baseline to three years
Favorable clinical outcome (modified Rankin score 0-2)
Time frame: Baseline to three years
Headache after CVT
Headache Impact Test - 6 score
Time frame: Baseline to three years
Incidence of hemorrhagic complication
Extracranial hemorrhage (fall in hemoglobin of 2 gram/dl or more within 48 hours) or intracranial hemorrhage
Time frame: Baseline to three years
Recanalization rate of cerebral venous system
Time frame: Baseline to three years
Incidence of epilepsy
Time frame: Baseline to three years
Incidence of acute ischemic stroke
Time frame: Baseline to three years
Incidence of pulmonary embolism
Time frame: Baseline to three years
Psychological distress after CVT
Population Health Questionnaire (PHQ)-9 score
Time frame: Baseline to three years
Ran from Aug 2022 to primary completion in Dec 2023, 16 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.